Biotechnology firm Creative Biolabs has unveiled critical advancements in antibody-drug conjugate (ADC) development, potentially transforming approaches to targeted cancer treatment and molecular imaging. The company's innovations center on sophisticated engineering of immunoglobulin G Fc regions and novel conjugation strategies.
By precisely modifying glycosylation sites in the Fc region, researchers have enhanced ADCs' ability to interact with complement proteins and cell receptors. This technological breakthrough significantly improves the targeted killing capabilities and stability of ADC therapies, addressing longstanding challenges in cancer treatment.
The company has developed groundbreaking bispecific ADCs that can simultaneously target two non-overlapping epitopes, offering a more nuanced approach to treating complex diseases. These innovative constructs target key cancer markers including HER2, EGFR, c-MET, and CD38, potentially increasing treatment efficacy while minimizing side effects.
Beyond cancer therapies, Creative Biolabs has also made notable progress in antibody-oligonucleotide conjugates (AOC). Using advanced technologies like DNA-PAINT imaging, these conjugates enable super-resolution imaging of intracellular molecules, providing researchers with powerful tools for understanding disease mechanisms.
With 17 approved ADCs currently on the global market and over 100 in various research stages, the company's developments represent a significant contribution to a rapidly evolving field. Their comprehensive development services—spanning target screening, antibody design, and drug conjugation—position them at the forefront of precision medical research.
